Myeloma Equipment
-
Manufactured by Creative Bioarraybased in USA
The NB-4 cell line was derived from the marrow of a patient with acute promyelocytic leukemia (APL; M3 in the FAB nomenclature) in second relapse in ...
-
Manufactured by Fate Therapeutics, Inc.based in USA
In addition to CD38 targeting in multiple myeloma, targeting of other tumor-associated cell-surface proteins has been clinically investigated. Of these antigens, the TNF-superfamily member B-cell Maturation Antigen (BCMA) is among the most researched. Several clinical trials in multiple myeloma have shown promising initial results targeting ...
-
Manufactured by Fate Therapeutics, Inc.based in USA
Multiple myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow and produce abnormal antibodies called M proteins, which can cause kidney damage, bone destruction, and impaired immune function. While multiple approved ...
-
Manufactured by Antengene Corporation Limitedbased in CHINA
Multiple myeloma is caused by the dysregulated proliferation of plasma cells, characterized by the proliferation of monoclonal plasma cells that results in an overabundance of monoclonal immunoglobulin or its fragment (M protein). Clinical manifestations of MM include hypercalcemia, renal insufficiency, anemia, and the destruction of the bone. ...
-
Manufactured by Athens Research & Technology Inc.based in USA
In normal adult serum, the approximate percentage composition of IgA with respect to is subclasses is IgA1:90% and IgA2:10%. In secretory IgA, the subclass proportions may approach 50:50. The clinical significance of the subclasses has yet to be ...
-
Manufactured by Celyad Oncologybased in BELGIUM
CYAD-211 is a short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of relapsed or refractory multiple myeloma (r/r MM). CYAD-211 is engineered to co-express a B-cell maturation antigen (BCMA) chimeric antigen receptor and a single shRNA hairpin which interferes with the expression of the CD3ζ component of the ...
-
Manufactured by Sana Biotechnologybased in USA
Oncology - Multiple ...
-
Manufactured by Sana Biotechnologybased in USA
Oncology: Multiple ...
-
Manufactured by Sana Biotechnologybased in USA
Oncology: Multiple ...
-
Manufactured by ALL Chemistry Inc.based in USA
SC99 is a selective inhibitor of JAK2-STAT3 activation. SC99 downregulates the expression of STAT3-modulated genes.SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic ...
-
based in USA
Production of monoclonal antibodies (mAbs) is central to all efforts at DxDiscovery. MAb production begins with immunization of a mouse with an antigen. Several weeks after immunization, spleen cells are harvested. B cells in the spleen produce antibody but cannot grow in culture. The spleen cells are fused with cells of a myeloma ...
-
by Genmab A/Sbased in DENMARK
Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.1 Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from ...
-
Manufactured by Takeda Pharmaceutical Company Limitedbased in JAPAN
Bortezomib (brand name: Velcade) is a treatment for multiple myeloma (a cancer of the plasma cells) and mantle cell lymphoma (a cancer of the lymph ...
-
based in USA
STAR-LLD is in development in two continuous delivery systems: subcutaneous and transdermal. STAR-LLD is in development for new multiple myeloma indications for lenalidomide and achievement of superiority versus oral lenalidomide in maintenance treatment of multiple myeloma. The STAR-LLD delivery system is expected to provide ...
-
Manufactured by LAVA Therapeutics N.V.based in NETHERLANDS
Our lead program, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). We have achieved preclinical proof-of-concept with LAVA-051 by demonstrating efficacy and safety in a variety of preclinical models. ...
-
by Huabiobased in USA
Monoclonal antibodies (mAbs) are created by immunizing a mouse with a target antigen, thereby eliciting an immune response. The B lymphocytes, taken from the immunized mouse spleen, produce antibodies to the antigen. Each B lymphocyte is then fused with an immortal myeloma cell line, allowing the production of unlimited quantities of ...
-
Manufactured by Sino Biological Inc.based in USA
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with a synthetic peptide corresponding to the C-terminus of the Human Histone H3. The IgG fraction of the cell culture supernatant was purified by Protein A affinity ...
-
Manufactured by Sino Biological Inc.based in USA
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human EGFR / ErbB / HER1 (rh EGFR / ErbB / HER1; Catalog #10001-H08H; Met 1-Ser 645; NP_005219). The IgG fraction of the cell culture supernatant was purified by Protein A ...
-
Manufactured by SYnAbs S.A.based in BELGIUM
in the first place, based upon an exclusive asset: the rat-LOU species and rat-LOU IR983 myeloma cell line, developed in 1983 by Hervé Bazin in Catholique University of Louvain-la-Neuve (UCL). ...
-
based in USA
cancer, the Company believes that narazaciclib (ON 123300) may also present an innovative approach to treating other cancers including mantle cell lymphoma, multiple myeloma, advanced colorectal cancer, hepatocellular carcinoma and inoperable ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you